Prologue
Introduction
The Pan American Health Organization's Perspective
The Viewpoint of the Inter-American Institute for Cooperation in Agriculture
I. EMERGING CONNECTIONS BETWEEN BIODIVERSITY AND BIOTECHNOLOGY: BIOPROSPECTING MODELS
Costa Rica's National Institute for Biodiversity (INBio)
Chemical Prospecting: An Overview of the International cooperative Biodiversity Groups Program
Bioprospecting in the Information Age: A Critical Analysis of Conservation-Linked Pharmaceutical Searches through Biodiversity
Andes Pharmaceuticals, Inc.: A New Model for Biodiversity Prospecting
Annex I. Typology of Some Experiences Related to Bioprospecting
Annex II. Source Country Benefits from Collaborations
II. THE NEXUS BETWEEN BIODIVERSITY AND BIOTECHNOLOGY IN PHARMACEUTICALS AND AGRICULTURE
Drug Discovery and Biodiversity: Collaborations and Risks in the Discovery of New Pharmaceuticals
Biodiversity and Biotechnology: Approaches to Sustainable Agricultural Development
III. POLITICS AND POLICIES
From Medicinal Plants to Natural Pharmaceuticals: The Marketing of Nature
Evaluating Host Country and International Policy Options for Biochemical Prospecting
IV. ECONOMIC VALUATION OF BIODIVERSITY
Economic Valuation of Biodiversity for Agriculture
Economic Analysis of Biodiversity as a Source of Pharmaceuticals
V. LEGAL ISSUES: INTELLECTUAL PROPERTY RIGHTS AND CONTRACTS
Legal Issues: Contracts, Intellectual Property Rights, and Other Property Rights
Indigenous Knowledge and Intellectual Property: Towards Equitable Compensation
Economic Analysis of Contractual Arrangements for Biochemical Prospecting
VI. EPILOGUE
Summary, Concluding Remarks, and Policy Options
Commentary: Will Biodiversity Prospecting for Pharmaceuticals Lead to the Discovery of "Green Gold"?